Inogen | INGN - Equity Capital And Reserves


Inogen reported $197.18M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Abbott USD 52.06B 69M Mar/2026
Accuray USD 53.42M 8.45M Dec/2025
AngioDynamics USD 176.33M 2.52M Sep/2025
Artivion USD 450.47M 2.24M Mar/2026
AtriCure USD 491.69M 242K Mar/2026
Baxter International USD 6.04B 86M Mar/2026
Becton, Dickinson and Co. USD 24.13B 1.15B Mar/2026
Boston Scientific USD 25.86B 1.63B Mar/2026
Chart Industries USD 3.16B 73.1M Mar/2026
Cooper Companies USD 8.36B 124.7M Dec/2025
Dexcom USD 2.96B 210.9M Mar/2026
Edwards Lifesciences USD 10.33B 10.1M Mar/2026
Globus Medical USD 4.73B 159.06M Mar/2026
Inogen USD 197.18M 2.32M Sep/2025
Insulet USD 1.3B 212.6M Mar/2026
Masimo USD 788.9M 67.7M Mar/2026
Medtronic USD 48.99B 128M Dec/2025
Orthofix International USD 435.19M 14.85M Mar/2026
Philips EUR 11.39B 403M Mar/2026
ResMed USD 6.49B 171.03M Mar/2026
Steris USD 7.15B 145.4M Dec/2025
Stryker USD 22.42B 635M Dec/2025
Tandem Diabetes Care USD 132.4M 22.77M Mar/2026
Teleflex USD 3.08B 40.33M Mar/2026
X T L Biopharmaceuticals USD -47K 5.48M Jun/2025
Zimmer Biomet Holdings USD 12.68B 16.1M Mar/2026